Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carmustine in BRCA1/2-associated advanced breast and ovarian cancer
2013-002036-24Phase 2Terminated
- Sponsor
- University of Cologne
- Start
- Jan 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carmustine in breast cancer and ovarian cancer, sponsored by University of Cologne. Primary endpoints: Tumor response after 2 cycles and Tumor response after 4 cycles. Started Jan 2014; status: terminated.
02
Drugs
carmustine
03
Conditions
breast cancerovarian cancer
Beyond the preview
Go deeper on 2013-002036-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002036-24.